ISRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Intuitive Surgical Inc (ISRG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong growth trends in its financials, positive news sentiment, and significant congressional purchases, all of which support a bullish outlook. Despite some neutral technical indicators, the overall long-term growth potential and analyst optimism make this a solid investment opportunity.
The MACD histogram is positive at 4.11 and expanding, indicating bullish momentum. RSI is neutral at 62.966, suggesting no overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. Key support is at 480.842, and resistance is at 508.384, with the stock trading near resistance levels.
Strong financial performance in Q4 2025, with revenue up 18.76% YoY and EPS up 17.55% YoY.
Positive news sentiment, including an 18% YoY increase in surgeries performed using da Vinci systems and a growing installation base of 11,106 systems.
Congressional trading data shows 4 purchase transactions totaling $1.5M-$5.0M, indicating confidence from influential figures.
Analysts are optimistic, with multiple upgrades and price target increases, including a high target of $750.
Gross margin dropped to 66.44%, down -2.35% YoY, which could indicate rising costs or pricing pressures.
UBS recently lowered its price target to $570 from $600, citing a neutral stance.
In Q4 2025, revenue increased by 18.76% YoY to $2.87B, net income rose by 15.91% YoY to $794.8M, and EPS grew by 17.55% YoY to $2.21. However, gross margin declined by 2.35% YoY to 66.44%. Overall, the company shows strong growth trends despite slight margin compression.
Analysts are generally bullish on ISRG, with multiple buy ratings and price target increases. Notable upgrades include Freedom Capital's target of $610 and Barclays' target of $712. The highest target is $750 from Bernstein, citing strong EPS growth and margin performance. UBS, however, maintains a neutral stance with a lower target of $570.
